US Patent 11464847 Lassa virus vaccine
Patent 11464847 was granted and assigned to CureVac on October, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 11 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 7 Dec, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 18 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 23 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
114648470
Date of Patent
October 11, 2022
0Patent Application Number
164715440
Date Filed
December 22, 2017
0Patent Primary Examiner
Edits on 12 Oct, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
Article (+501 characters)
US Patent 11464847 Lassa virus vaccine
Article
The present invention provides mRNAs usable as vaccines against lassa virus (LASV) infections. Further, the invention relates to (pharmaceutical) compositions and vaccines comprising said mRNAs and their use for treatment or prophylaxis of a lassa virus infection. The present invention further features a kit comprising the mRNAs, (pharmaceutical) compositions or vaccines and a method for treatment or prophylaxis of lassa virus infections using said mRNAs, pharmaceutical) compositions or vaccines.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
114648470
Date of Patent
October 11, 2022
0Patent Application Number
164715440
Date Filed
December 22, 2017
0Patent Primary Examiner
Find more entities like US Patent 11464847 Lassa virus vaccine
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
